Sandbox: wdx causes: Difference between revisions

Jump to navigation Jump to search
Line 32: Line 32:
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Asplenia
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Asplenia
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hepatosplenomegaly
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hepatosplenomegaly
! rowspan="2" |Lymphadenopathy
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lymphadenopathy
! rowspan="2" |Joint redness
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Joint redness
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC
Line 39: Line 39:
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP
! rowspan="2" |BUN/Cr
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BUN/Cr
! rowspan="2" |LFT
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |LFT
|-
|-
!autonomous
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |autonomous
!reactive
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |reactive
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
Line 52: Line 52:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 65: Line 62:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 74: Line 69:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |'''Hereditary chronic neutrophilia'''
! align="center" style="background:#DCDCDC;" |Hereditary chronic neutrophilia
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 95: Line 99:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 104: Line 106:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |'''Myeloproliferative neoplasms'''
! align="center" style="background:#DCDCDC;" |Myeloproliferative neoplasms
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 125: Line 129:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 134: Line 136:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 142: Line 142:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 155: Line 152:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 164: Line 159:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |'''Microangiopathic hemolytic anemia (MAHA)'''
! align="center" style="background:#DCDCDC;" |Microangiopathic hemolytic anemia (MAHA)
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 185: Line 189:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 194: Line 196:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!'''Leukoerythroblastosis'''
!Leukoerythroblastosis
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Immature thrombocytopenia
! align="center" style="background:#DCDCDC;" |Immature thrombocytopenia
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 245: Line 242:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 254: Line 249:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 292: Line 292:
|-
|-
!'''Leukocyte adhesion deficiency'''
!'''Leukocyte adhesion deficiency'''
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|-
|-
!'''Cryopyrin-associated periodic syndromes'''
!'''Cryopyrin-associated periodic syndromes'''
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |Rheumatoid arthritis
! align="center" style="background:#DCDCDC;" |Rheumatoid arthritis
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 367: Line 364:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 376: Line 371:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 384: Line 384:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 397: Line 394:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 406: Line 401:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
!adult Still's disease
!adult Still's disease
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|-
|-
!Kawasaki disease
!Kawasaki disease
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" |IBD
! align="center" style="background:#DCDCDC;" |IBD
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 487: Line 484:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 496: Line 491:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |

Revision as of 18:48, 13 September 2018

Differentiating Leukocytosis from Other Diseases

  • Leukocytosis is defined as an elevated white blood cell (WBC) count greater than 11,000 per mm3 (11.0 × 109 per L).
  • The most common type of leukocytosis is neutrophilia.
    • Neutrophilia can be defined as an increase in the absolute number of mature neutrophils to greater than 7,000 per mm3 [7.0 × 109 per L].
Category Condition Etiology Mechanism Congenital Acquried Clinical manifestations Para−clinical findings Gold standard Associated findings
Demography History Symptoms Signs
Lab Findings
Physiologic increased bone marrow production demargination of peripheral blood neutrophils Appearance Fever Abdominal pain BP Asplenia Hepatosplenomegaly Lymphadenopathy Joint redness Other CBC PBS Bone marrow exam ESR/CRP BUN/Cr LFT
autonomous reactive WBC HB Plt
Hematologic Hereditary neutrophilia
Hereditary chronic neutrophilia
Myeloproliferative neoplasms
Polycythemia Vera
Microangiopathic hemolytic anemia (MAHA)
Leukoerythroblastosis
Immature thrombocytopenia
Immunology/

Rheumatology

Condition Etiology Physiologic Autonomous increased bone marrow production Reactive increased bone marrow production demargination of peripheral blood neutrophils Congenital Acquried Demography History Appearance Fever Abdominal pain BP Asplenia Hepatosplenomegaly Lymphadenopathy Joint redness Other signs WBC HB Plt PBS Bone marrow exam ESR/CRP BUN/Cr LFT Gold standard Associated findings
Leukocyte adhesion deficiency
Cryopyrin-associated periodic syndromes
Rheumatoid arthritis
Juvenile onset rheumatoid arthritis
adult Still's disease
Kawasaki disease
IBD
Sarcoidosis
Chronic hepatitis
Sweet syndrome
Acute Gout
Infections Acute bacterial toxic granulations, Döhle bodies, and cytoplasmic vacuoles in neutrophils
Chronic
Viral infection Children
granulomatous infections
bronchiectasis
Metabolic Diabetic coma
Acidosis
Thyroid strom
Hypercortisolism
Seizures
Category Condition Etiology Physiologic Congenital Acquried Demography History Appearance Fever Abdominal pain BP Asplenia Jaundice Other signs Plt HB WBC PBS Bone marrow exam ESR/CRP Gold standard Associated findings
Medications Steriod Release of granulocytes from the bone marrow
myeloid growth factors
Lithium
Beta agonists
Cytokines
Catecholamines (epinephrine) Stimulation of bone marrow myelopoiesis and/or egress into the circulation
ATRA
Other Allergy
Post splenectomy
Down syndrome
Cigarette smoking
Stress/Exercise
Infancy
Pregnancy
Platelet clumping Spurious
Mixed cryoglobulinemia Spurious
Category Condition Etiology Physiologic Congenital Acquried Demography History Appearance Fever Abdominal pain BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam ESR/CRP Gold standard Associated findings